Corporatism and big pharma
The pharmaceutical industry has leveraged public policy to its benefit, prohibiting the federal government from discounts on drug prices through bulk purchases while using the tax code to develop Patient Assistance Foundations to claim charitable contributions as well as justifying moving income overseas to reduce tax liability. Consumers and taxpayers are left covering the costs of Big Pharma's corporatism. Regulatory reforms are proposed to make drug companies more socially responsible.
Ethical Human Psychology and Psychiatry
First Page Number
Last Page Number
Stoesz, David; Robinson, Myra; Carrero-Iglesia, Yomaira; Curry, Desiree; Selph, Tylencia; and Sidoti, Rebecca, "Corporatism and big pharma" (2016). Kean Publications. 1785.